298 related articles for article (PubMed ID: 19593196)
1. Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder".
Hashimoto K
J Clin Psychopharmacol; 2009 Aug; 29(4):411-2; author reply 412. PubMed ID: 19593196
[No Abstract] [Full Text] [Related]
2. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
Preskorn SH; Baker B; Kolluri S; Menniti FS; Krams M; Landen JW
J Clin Psychopharmacol; 2008 Dec; 28(6):631-7. PubMed ID: 19011431
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
[TBL] [Abstract][Full Text] [Related]
4. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder.
Ratti E; Bellew K; Bettica P; Bryson H; Zamuner S; Archer G; Squassante L; Bye A; Trist D; Krishnan KR; Fernandes S
J Clin Psychopharmacol; 2011 Dec; 31(6):727-33. PubMed ID: 22020354
[TBL] [Abstract][Full Text] [Related]
5. [Ketamine for treatment of acute depression].
Hjerrild S; Bjerre J; Pedersen RH; Videbech P
Ugeskr Laeger; 2013 Sep; 175(37):2090-3. PubMed ID: 24011203
[TBL] [Abstract][Full Text] [Related]
6. Ketamine followed by memantine for the treatment of major depression.
Kollmar R; Markovic K; Thürauf N; Schmitt H; Kornhuber J
Aust N Z J Psychiatry; 2008 Feb; 42(2):170. PubMed ID: 18197514
[No Abstract] [Full Text] [Related]
7. Glutamate-based antidepressants: 20 years on.
Skolnick P; Popik P; Trullas R
Trends Pharmacol Sci; 2009 Nov; 30(11):563-9. PubMed ID: 19837463
[TBL] [Abstract][Full Text] [Related]
8. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder.
Heresco-Levy U; Javitt DC; Gelfin Y; Gorelik E; Bar M; Blanaru M; Kremer I
J Affect Disord; 2006 Jul; 93(1-3):239-43. PubMed ID: 16677714
[TBL] [Abstract][Full Text] [Related]
9. Ketamine as an alternative treatment for treatment-resistant depression.
Dowben JS; Grant JS; Keltner NL
Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
[No Abstract] [Full Text] [Related]
10. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases.
Paul R; Schaaff N; Padberg F; Möller HJ; Frodl T
World J Biol Psychiatry; 2009; 10(3):241-4. PubMed ID: 19224412
[TBL] [Abstract][Full Text] [Related]
11. N-methyl-D-aspartate glutamate receptor antagonists and the promise of rapid-acting antidepressants.
Krystal JH
Arch Gen Psychiatry; 2010 Nov; 67(11):1110-1. PubMed ID: 21041611
[No Abstract] [Full Text] [Related]
12. The short- and long-term efficacy of paroxetine HCl: A. Data from a 6-week double-blind parallel design trial vs. imipramine and placebo.
Peselow ED; Filippi AM; Goodnick P; Barouche F; Fieve RR
Psychopharmacol Bull; 1989; 25(2):267-71. PubMed ID: 2532373
[No Abstract] [Full Text] [Related]
13. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions.
Correll GE; Futter GE
Pain Med; 2006; 7(1):92-5. PubMed ID: 16533209
[No Abstract] [Full Text] [Related]
14. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.
Papakostas GI; Fava M
Eur Neuropsychopharmacol; 2009 Jan; 19(1):34-40. PubMed ID: 18823760
[TBL] [Abstract][Full Text] [Related]
15. Sustained effects of phenelzine and tranylcypromine on orthostatic challenge in antidepressant-refractory depression.
Tulen JH; Volkers AC; van den Broek WW; Bruijn JA
J Clin Psychopharmacol; 2006 Oct; 26(5):542-4. PubMed ID: 16974207
[No Abstract] [Full Text] [Related]
16. Intravenous ketamine for treatment-resistant major depressive disorder.
Covvey JR; Crawford AN; Lowe DK
Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range study.
Modell S; Naber D; Holzbach R
Pharmacopsychiatry; 1996 Mar; 29(2):63-6. PubMed ID: 8741023
[TBL] [Abstract][Full Text] [Related]
18. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.
Downey D; Dutta A; McKie S; Dawson GR; Dourish CT; Craig K; Smith MA; McCarthy DJ; Harmer CJ; Goodwin GM; Williams S; Deakin JF
Eur Neuropsychopharmacol; 2016 Jun; 26(6):994-1003. PubMed ID: 27133029
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled study of memantine in the treatment of major depression.
Zarate CA; Singh JB; Quiroz JA; De Jesus G; Denicoff KK; Luckenbaugh DA; Manji HK; Charney DS
Am J Psychiatry; 2006 Jan; 163(1):153-5. PubMed ID: 16390905
[TBL] [Abstract][Full Text] [Related]
20. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
Wade AG; Schlaepfer TE; Andersen HF; Kilts CD
J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
